Auna Announces 3Q26 Financial Results

Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Improves to 3.5x

Luxembourg, November 17, 2026 – Auna (NYSE: AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today unaudited financial results for the third quarter ended September 30, 2026 ("Third quarter 2026" or "3Q26"). Financial results are expressed in Peruvian Soles ("S/" or "PEN" or "Soles") and are presented in accordance with International Financial Reporting Standards ("IFRS"), unless otherwise noted.

3Q'26 Consolidated Highlights

- Revenue increased 10% YoY FXN and 19% YoY as reported to S/1,325 million, with sequential growth of 3% FXN and 7% as reported
- Adjusted EBITDA was S/231 million, decreasing 4.6% FXN while remaining flat as reported. Sequentially, Adjusted EBITDA was stable FXN and increased 2% as reported
- Mexico Segment Adjusted EBITDA increased 5% YoY in local currency, marking its first year-over-year growth in 2026
- Adjusted EBITDA Margin of 17.5%, compared to 18.4% in 2Q26
- Year to date Net Cash from Operating Activities increased 62% YoY to S/713 million, while Free Cash Flow increased 95% to S/626 million
- Leverage Ratio improved to 3.5x
- Oncology MLR remained stable at 50.7%
- Number of surgeries increased 12% YoY to 23,932
- Number of days hospitalized increased 6% YoY to 144,041
- Number of chemotherapy and radiotherapy sessions increased 7% YoY

Recent Developments

Centro Ambulatorio Trecca Public-Private Partnership Enters Construction Phase

On November 3, 2026, Centro Ambulatorio Trecca formally entered its construction phase following the fulfillment of all conditions precedent under Auna's Public-Private Partnership (PPP) with EsSalud. This milestone keeps the project on schedule and represents an important step in expanding access to quality healthcare in Peru. The commencement was marked by an event attended by national authorities, including the President of the Republic of Peru, Keiko Fujimori, as well as EsSalud representatives and Auna's leadership.

Structured as a 20-year, capital-light concession ring-fenced at the project level, construction expenditures will be reimbursed through progress certificates. The 23-story facility will provide Auna with access to a largely untapped segment of Peru's healthcare market serving approximately six million EsSalud-insured residents in Lima. Once operational, currently expected by late 2028, the facility is projected to increase EsSalud's healthcare capacity in metropolitan Lima by approximately 20% and support more than three million patient visits annually. Operations will be supported by monthly EsSalud payments based on contractually established minimum service volumes, providing long-term revenue visibility.

Full-Year 2026 Guidance Update

As announced on October 22, 2026, Auna reaffirms its full-year revenue guidance within the previously announced range of 10% to 14% FX-neutral growth and capital expenditures guidance of approximately 4% of consolidated revenues.

Auna revised its full-year 2026 Adjusted EBITDA outlook, reflecting higher-than-anticipated operating costs in Colombia, including adverse medical-costs under a specific oncology risk-sharing contract and regulatory price caps on certain high-cost oncology medications. The Company now expects full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year, compared to its previous guidance of 10% to 14% FX-neutral growth.

Message from Auna's Executive Chairman and President

The third quarter of 2026 reflected continued strong commercial momentum across our markets, with revenue increasing 10% on an FX-neutral basis. Adjusted EBITDA declined 5% FX-neutral, primarily reflecting profitability pressures in Colombia and Peru, partially offset by improving performance in Mexico. The quarter marked an important milestone

in Mexico's operational recovery, with Segment Adjusted EBITDA returning to year-over-year growth, while continued strong cash generation supported further deleveraging.

In Peru, our resilient integrated model produced revenue growth of 6% year-over-year. The Peru Healthcare network benefited from strong surgical volumes, up 21%, alongside a greater focus on high-complexity procedures. At Oncosalud, we prioritized and grew higher-retention B2B accounts, including two new agreements to onboard 4,000 members. Adjusted EBITDA was impacted by penalties arising from the reconciliation of prior years' receivables, as well as higher pharmacy and clinical payroll costs associated with increased patient volumes.

In Mexico, we are seeing tangible results from the commercial and operational initiatives implemented earlier this year. Segment Adjusted EBITDA increased 5% year-over-year in local currency, marking its first quarter of year-over-year growth in 2026. This improvement was driven by strong performance in the Monterrey Healthcare network, supported by higher surgical and oncology volumes and improved capacity utilization, which more than offset softer results at Auna Seguros following changes in VAT deductibility. With double-digit oncology revenue growth and improving operating efficiency, we remain focused on further improving this recovery and translating higher utilization into stronger profitability.

In Colombia, revenue increased 12% in local currency, supported by increased hospital capacity in Montería and continued growth in our PGP arrangements. However, Segment Adjusted EBITDA declined 30% in local currency, primarily reflecting two items: first, extraordinary adverse medical-costs under a specific oncology risk-sharing contract, where utilization and treatment costs significantly exceeded contractual assumptions; and second, regulatory price caps on certain high-cost oncology medications. These were further compounded by higher personnel costs across the segment. We have terminated the risk sharing contract to limit further exposure as it represented approximately 4% of Colombia´s revenues and have engaged legal counsel to review all recovery options under the contract. We remain focused on strengthening contract economics, improving operating efficiency, and restoring profitability.

Consolidated cash flow generation remained a significant strength of our platform. Year-to-date Net Cash from Operating activities increased 62% year-over-year to S/713 million, while Free Cash Flow increased 95% to S/626 million, supported by disciplined working capital management, and lower tax payments. This performance contributed to a reduction in net debt and an improvement in our leverage ratio towards 3.5x, bringing it closer to our medium-term target of below 3.0x.

We reached an important milestone with the commencement of construction of Centro Ambulatorio Trecca in Lima. This capital-light public-private partnership will significantly expand our addressable market and provide long-term contractual revenue visibility, reinforcing our strategy of developing capital-efficient growth opportunities.

Looking ahead, as discussed at our recent 2026 Investor Day, we remain confident in the underlying growth trajectory of our business. We reaffirm our full-year 2026 revenue guidance, expecting FX-neutral growth within our 10% to 14% range. However, reflecting the profitability pressures discussed above, particularly in Colombia, we now expect full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year. Capital expenditures guidance remains unchanged at approximately 4% of revenues.

We remain focused on accelerating growth in Mexico, restoring profitability in Colombia, improving earnings quality and operating efficiency in Peru, and translating our commercial momentum into even stronger cash generation and growing, sustainable returns for our shareholders. We are committed to disciplined execution, strengthening our financial performance, and creating long-term shareholder value.

Overview of 3Q26 Consolidated Results

Revenues increased 10% YoY FXN and 19% as reported to S/1,325 million, with growth measured in local currency ("LC") across all three markets: 16% in Mexico, 6% in Peru, and 12% in Colombia. In Mexico, growth was driven by higher surgery and oncology volumes at the Monterrey Healthcare network, partially offset by softer performance in Auna Seguros. In Peru, revenue growth was supported by increased healthcare activity, particularly high-complexity procedures and continued growth in Oncosalud's B2B business. In Colombia, revenue growth benefited from expanded hospital capacity.

Adjusted EBITDA decreased 5% YoY FXN and remained flat as reported at S/231 million, with an Adjusted EBITDA margin of 17.5%. In LC, Segment Adjusted EBITDA increased 5% in Mexico, while declining 6% in Peru and 30% in Colombia. Mexico recorded its first quarter of year-over-year Segment Adjusted EBITDA growth in 2026, driven by improving profitability in the Monterrey Healthcare network, partially offset by softer results at Auna Seguros. In Peru, profitability was impacted by penalties related to the reconciliation of prior years' receivables, as well as higher MLR from a larger mix of healthcare plans and the ramp up of new B2B oncology plans. In Colombia, profitability was primarily affected by adverse medical-costs under a specific oncology risk-sharing contract, which Auna has since terminated and regulatory price caps on certain high-cost oncology medications.

Reported results were impacted by foreign exchange fluctuations, including a 3% appreciation of the Mexican Peso (MXN) and a 20% appreciation of the Colombian Peso (COP) both against the Peruvian Sol (PEN).

Net finance costs were S/112 million in 3Q26, compared to S/72 million in 3Q25. The increase primarily reflected a S/40 million non-cash FX gain recognized in 3Q25 that did not recur in 3Q26, due to Auna resetting its USD/PEN call spread to 3.40-3.80 in Q425. The remainder of the change was due to an increase in Finance costs consisting of (i) a S/6 million non-cash finance expense related to the future purchase obligation for IMAT Oncomedica in 3Q26 versus S/1 million in 3Q25; and (ii) Interest expense and other costs of S/114 in 3Q26 versus S/115 in 3Q25, and partially offset by Finance income of S/7 million in 3Q26 versus S/4 million in 3Q25. Excluding non-cash effects, Net finance costs were S/107 million in 3Q26, compared to S/110 million in 3Q25.

Net Income was S/24 million in 3Q26, compared to S/53 million in 3Q25 primarily reflecting the absence of the significant S/40 million non-cash FX gain recorded in the prior-year period, partially offset by S/20 million in lower income tax expenses. On a per-share basis, Net Income was S/0.27, based on a weighted average of 74,235,734 basic and diluted shares.

Adjusted Net Income was S/35 million in 3Q26, compared to S/58 million in 3Q25, primarily reflecting the non-cash FX effects described above, partially offset by lower income tax expenses. On a per-share basis, Adjusted Net Income was S/0.41, based on a weighted average of 74,235,734 basic and diluted shares.

Business performance

HEALTHCARE SERVICES MEXICO

(Explanations of variances are in local currency unless expressed otherwise)

Auna's Healthcare Services and Auna Seguros' operations in Mexico accounted for 24% of consolidated revenues and 36% of consolidated Adjusted EBITDA in the quarter.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

					Δ 3Q'26 vs 3Q'25		Δ 3Q'26 vs 2Q'26		Δ YTD 26 vs YTD 25	
Healthcare Services Mexico Key Operating Metrics		**3Q'26 (USD)**	**3Q'26**	**YTD 26**	**As Reported**	**L.C.**	**As Reported**	**L.C.**	**As Reported**	**L.C.**
Beds	#		708	708	0%		0%		0%	
Surgeries	# (000)		6	16	12%		12%		7%	
Emergency treatments	# (000)		8	24	9%		1%		1%	
Radiotherapy & Chemotherapy	# (000)		5	14	34%		-1%		62%	
Total number of days hospitalized	# (000)		27	77	5%		6%		2%	
Operating capacity utilization	%		50.5%	49.0%	2.9 p.p.		0.6 p.p.		1.3 p.p.	
Total capacity utilization	%		41.1%	39.9%	2.0 p.p.		2.0 p.p.		0.7 p.p.	
Key Financial Metrics										
Segment Revenue		92	316	895	20%	16%	5%	6%	15%	9%
Segment Adjusted EBITDA		24	83	234	8%	5%	7%	8%	-4%	-9%
Segment Adjusted EBITDA margin	%		26.3%	26.2%	-2.7 p.p.		0.4 p.p.		-5.2 p.p.	

Segment revenue in Mexico increased 16% YoY in LC, driven by an 18% increase in the Monterrey Healthcare Services network. Sequentially, Segment revenue grew 6% compared to 2Q26, with Healthcare Services remaining the primary growth driver. Growth was supported by higher volumes across surgeries, intensive care, and chemotherapy sessions, reflecting the continued benefits of operational initiatives implemented in previous quarters.

Auna continued to benefit from improved tier classifications with two key payors at Doctors Hospital ("DH"), its largest healthcare facility, where patient volumes associated with these payors increased 25% and related revenues surged 63% YoY. Total surgery revenues at DH also increased 22% YoY. Additionally, the renewal of the ISSSTELEON B2B agreement at OCA, which included improved pricing that reflects the complexity of services provided, contributed to a 16% YoY increase in related revenues. Private out-of-pocket revenues across the network increased 11% YoY, while patient volumes from surgical and hemodynamic packages tripled over the same period.

In oncology, radiotherapy and chemotherapy revenues increased 73% YoY and 5% QoQ, representing 10% of Monterrey's network revenues in 3Q26, up from 7% in 3Q25.

Operationally, approximately 52% of the network's productive physicians increased their service volumes during the quarter, while nursing staffing coverage and retention improved compared to 2025. The network also strengthened physician onboarding criteria, with a greater focus on productivity. During the quarter, Auna onboarded 28 physicians who actively treated patients for at least two months and met minimum billing thresholds, primarily in specialties including traumatology, cardiology, and general medicine.

Higher volumes across surgeries, emergency treatments, hospitalizations, and intensive care contributed to total capacity utilization of 41.1%, an increase of 2.0 percentage points both YoY and QoQ.

Segment Adjusted EBITDA increased 5% YoY in local currency, with an Adjusted EBITDA margin of 26.3%. This marked the segment's first quarter of year-over-year Adjusted EBITDA growth in 2026, reflecting continued progress in its operational recovery. Within the segment, the Monterrey Healthcare network's Adjusted EBITDA increased 10% YoY, reaching a margin of 28%, despite higher pharmacy costs related to changes in service mix, investments in talent retention, and the implementation of a new mandatory medical insurance benefit for employees.

Sequentially, Segment Adjusted EBITDA increased 8% in local currency, supported by 9% growth in the Monterrey Healthcare network's Adjusted EBITDA and a 0.7 percentage point improvement in its margin compared to 2Q26. These results provide further evidence of the ongoing recovery in the network's operating profitability.

Conversely, Auna Seguros revenues remained flat YoY, while Adjusted EBITDA was negatively impacted by a new 2026 sector-wide regulation restricting VAT deductibility for insurance products.

PERU OPERATIONS: HEALTHCARE SERVICES PERU AND ONCOSALUD PERU

Auna's Healthcare Services and Oncosalud Peru accounted for 39% of consolidated revenues and 45% of consolidated Adjusted EBITDA in the quarter.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Healthcare Services Peru and Oncosalud Peru Key Financial Metrics		3Q'26 (USD)	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ 3Q'26 vs 2Q'26	Δ YTD 26 vs YTD 25
Consolidated Revenue		**150**	**516**	**1,528**	**6%**	**1%**	**7%**
Healthcare Services Peru		89	307	885	*10%*	*4%*	*9%*
Oncosalud Peru		94	323	954	*10%*	*2%*	*11%*
Holding and Eliminations (*)			(114)	(310)	*35%*	*13%*	*24%*
Consolidated Peru Adjusted EBITDA		**30**	**104**	**304**	**-6%**	**3%**	**-3%**
Healthcare Services Peru		11	37	102	*-16%*	*6%*	*-15%*
Oncosalud Peru		20	68	202	*0%*	*1%*	*4%*
Consolidated Peru Adj. EBITDA margin	*%*		***20.2%***	***19.9%***	***-2.6 p.p.***	***0.4 p.p.***	***-2.1 p.p.***
Healthcare Services Peru			*11.9%*	*11.5%*	*-3.8 p.p.*	*0.2 p.p.*	*-3.2 p.p.*
Oncosalud Peru			*20.9%*	*21.2%*	*-2.0 p.p.*	*-0.1 p.p.*	*-1.4 p.p.*

(*) Relates to intersegment revenue elimination.

Healthcare Services Peru Key Operating Metrics		3Q'26 (USD)	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ 3Q'26 vs 2Q'26	Δ YTD 26 vs YTD 25
Beds	#		389	389	1%	0%	1%
Surgeries	*# (000)*		6	18	21%	10%	11%
Emergency treatments	*# (000)*		54	151	10%	4%	12%
Chemotherapies & Radiotherapies	*# (000)*		14	40	18%	6%	6%
Total number of days hospitalized	*# (000)*		32	94	6%	2%	8%
Operating capacity utilization	%		92.6%	91.4%	4.9 p.p.	0.6 p.p.	7.1 p.p.
Total capacity utilization	%		89.2%	88.1%	3.9 p.p.	0.6 p.p.	6.0 p.p.
Key Financial Metrics							
Revenue		89	307	885	10%	4%	9%
External revenues		60	*207*	*616*	3%	0%	5%
Intercompany revenue		29	*100*	*269*	29%	13%	21%
Segment Adjusted EBITDA		11	37	102	-16%	6%	-15%
Segment Adjusted EBITDA margin	%		*11.9%*	*11.5%*	*-3.8 p.p.*	*0.2 p.p.*	*-3.2 p.p.*

Oncosalud Peru Key Operating Metrics		3Q'26 (USD)	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ 3Q'26 vs 2Q'26	Δ YTD 26 vs YTD 25
Plan memberships	# (000)		1,442	1,442	3%	-2%	3%
Oncological Plans	*# (000)*		*973*	*973*	*-2%*	*-3%*	*-2%*
Average monthly revenue per plan membership		18.98	65.15	64.02	5%	3%	5%
Preventive check-ups	# (000)		25	82	-14%	-4%	-13%
Patients treated	# (000)		56	154	34%	10%	28%
MLR	%			58.7%			4.2 p.p.
Oncological Plans	*%*			*50.7%*			*1.4 p.p.*
Key Financial Metrics							
Revenue		94	323	954	10%	2%	11%
External revenues		*90*	*308*	*912*	*8%*	*1%*	*9%*
Intercompany revenue		*4*	*14*	*41*	*96%*	*9%*	*53%*
Segment Adjusted EBITDA		20	68	202	0%	1%	4%
Segment Adjusted EBITDA margin	*%*		*20.9%*	*21.2%*	*-2.0 p.p.*	*-0.1 p.p.*	*-1.4 p.p.*

Total revenue in Peru increased 6% YoY to S/516 million in 3Q26. Healthcare Services Peru revenue increased 10% YoY, supported by higher surgery, emergency, and oncology volumes. Emergency treatments increased 10% YoY, benefiting from commercial initiatives with corporate accounts, while surgeries grew 21%, alongside a greater focus on high-complexity procedures and higher average revenue per surgery. Total bed capacity increased 1% YoY to 389 beds, including the addition of four ICU beds. Hospitalization days increased 6% YoY, while total capacity utilization reached 89.2%, an improvement of 3.9 percentage points.

Oncosalud Peru revenue increased 10% YoY, supported by annual pricing adjustments and 3% growth in total plan memberships. Auna continued to prioritize B2B accounts with stronger retention characteristics, adding two new agreements to onboard 4,000 members beginning in 4Q26.

Preventive check-ups, as planned, declined 14% YoY, reflecting a more targeted approach to screening members at higher risk of developing breast, colorectal, cervical, or prostate cancers. Meanwhile, patients treated increased 34% YoY, driven by increased healthcare plan memberships and the initial utilization among newly onboarded B2B members.

Oncosalud's overall MLR increased 4.2 percentage points year-to-date to 58.7%, while the Oncology MLR increased 1.4 percentage points to 50.7%. The overall MLR increase reflects a greater mix of healthcare plans while the Oncology MLR increase reflects the initial higher average MLR from newly onboarded B2B accounts.

Consolidated Peru Adjusted EBITDA decreased 6% YoY to S/104 million in 3Q26, with an Adjusted EBITDA margin of 20.2%, compared to 22.8% in 3Q25. Profitability was impacted by higher pharmacy costs associated with the onboarding of new B2B accounts and

increased clinical and nursing payroll expenses to support growing hospitalization and emergency volumes while maintaining capacity and quality standards. Results were also affected by penalties related to billing matters arising from the reconciliation of prior years' receivables. Excluding impacts related to billing matters, EBITDA growth in the quarter would have been broadly stable YoY.

HEALTHCARE SERVICES COLOMBIA

(Explanations of variances are in local currency unless expressed otherwise)

Auna's Healthcare services operations in Colombia accounted for 37% of consolidated revenues and 19% of consolidated Adjusted EBITDA in the quarter.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

					Δ 3Q'26 vs 3Q'25		Δ 3Q'26 vs 2Q'26		Δ YTD 26 vs YTD 25	
Healthcare Services Colombia Key Operating Metrics		**3Q'26 (USD)**	**3Q'26**	**YTD 26**	**As Reported**	**L.C.**	**As Reported**	**L.C.**	**As Reported**	**L.C.**
Beds	#		1,155	1,155	2%		2%		2%	
Protected Lives	# (000)		3,209	3,209	6%		2%		6%	
Surgeries	# (000)		12	34	7%		8%		5%	
Emergency treatments	# (000)		39	116	6%		3%		5%	
Chemotherapies & Radiotherapies	# (000)		37	109	0%		4%		1%	
Total number of days hospitalized	# (000)		85	248	6%		5%		4%	
Operating capacity utilization	%		88.8%	86.8%	2.7 p.p		0.0 p.p		0.7 p.p	
Total capacity utilization	%		80.3%	78.5%	3.3 p.p		1.1 p.p		1.8 p.p	
Key Financial Metrics										
Revenue		144	494	1,321	34%	12%	16%	4%	25%	13%
Segment Adjusted EBITDA		13	43	145	-16%	-30%	-22%	-30%	-4%	-13%
Segment Adjusted EBITDA margin	%		*8.8%*	*10.9%*	*-5.1 p.p*		*-4.3 p.p*		*-3.3 p.p.*	

Segment revenue in Colombia increased 12% YoY in local currency, supported by a 6% increase in protected lives, 7% growth in surgeries, and 6% increases in both emergency treatments and hospitalization days. Chemotherapy and radiotherapy volumes remained stable YoY and increased 4% QoQ.

Operating performance benefited from expanded capacity at IMAT Oncomedica in Montería, capturing growing demand for high-complexity care. During 3Q26, the hospital reactivated 18 adult ICU beds and added 24 hospitalization beds.

Auna continued diversifying its payor base to reduce exposure to government-intervened payors. Revenues from intervened payors represented 15% of Colombia's segment revenues in 3Q26, compared to 16% in 3Q25. Private payor revenues increased 22% YoY, accounting for 18% of segment revenues.

PGP contracts in Antioquia, covering cardiovascular, ambulatory, and oncology services, accounted for 23% of Colombia's segment revenues, compared to 18% in 3Q25. These risk-sharing arrangements covered approximately 3.2 million lives at quarter-end, an increase of 6% YoY, and deliver more engagement with payors and their populations and greater cash flow predictability for Auna.

After the close of the quarter, the Company terminated an oncology risk-sharing contract that started in 2025 covering approximately 500,000 lives and represented approximately 4% of Colombia's revenues, following a significantly higher incidence of advanced-stage cancers than anticipated under the contractual assumptions agreed with the payor.

Revenues in Montería and Barranquilla increased 15% and 10% YoY, respectively, and together represented 47% of segment revenues. Total capacity utilization reached 80.3%, an increase of 3.3p.p. YoY, returning to levels observed in 2024, before the intervention of Nueva EPS.

Segment Adjusted EBITDA decreased 30% YoY in local currency, with an Adjusted EBITDA margin of 8.8%, compared to 13.9% in 3Q25. Margins were affected by government-imposed price caps on certain high-cost oncology medications impacting the quarter only partially since mid-August, as well as initial operating costs associated with the capacity expansion in Montería. Additional payroll pressures reflected mandatory wage increases and the statutory reduction in the standard workweek, which resulted in higher overtime expenses.

The decline was also driven by adverse medical costs related to the abovementioned oncology risk-sharing contract, where an unexpectedly high incidence of advanced-stage cancer cases among the covered population resulted in treatment costs exceeding the contractual assumptions. The contract was terminated after the close of the quarter to limit further exposure and protect future profitability.

Balance Sheet & Cash Flow

Consolidated Debt

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	Sep-26 (USD)	Sep-26	Dec-25	Sep-25	Δ Sep-26 vs Sep-25	Δ Sep-26 vs Dec-25
(+) Loans and borrowings	1,049	3,600	3,533	3,526	2%	2%
Short term debt	*135*	*465*	*316*	*658*	-29%	47%
Long term debt	*913*	*3,136*	*3,216*	*2,868*	9%	-2%
(+) Lease Liabilities	43	146	124	129	13%	18%
Gross Debt	**1,091**	**3,746**	**3,656**	**3,655**	**3%**	**2%**
(-) Cash and cash equivalents / marketable securities	179	614	335	226	172%	83%
Net Debt	**913**	**3,133**	**3,321**	**3,429**	**-8.6%**	**-5.7%**
Leverage Ratio		**3.5x**	**3.6x**	**3.6x**	**-0.1x**	**-0.1x**

Gross Debt at the close of 3Q26 increased 2%, or S/90 million, versus 4Q25, to S/3,746 million. This increase was driven mainly by non-cash FX effects rather than an increase in underlying debt. The net changes reflect: (i) a negative non-cash effect of S/97 million associated with the depreciation of the PEN against the COP, the USD and the MXN of 16%, 2% and 2%, respectively; and (ii) higher accrued interest of S/46 million related to the Term Loan maturing 2030 and 2032 Senior Secured Notes. These effects were partially offset by (iii) a S/52 million reduction in short-term debt.

Leverage Ratio improved to 3.5x at the end of 3Q26. Compared to 3Q25 this improvement reflects an increase in cash position at the end of the period, partially offset by lower Adjusted LTM EBITDA and slightly higher gross debt driven by the aforementioned non-cash FX effects. On a sequential basis, the ratio also improved due to the increase in cash. Auna remains committed to a medium-term leverage target of below 3.0x.

Consolidated Debt Amortization Profile

(Figures in millions of Soles, unless expressed otherwise)

	Total	Leases	Y1	Y2	Y3	Y4	Y5	Y6+
Loans and Borrowings	3,600		465	270	350	760	463	1,292
Financial Leases	53		16	10	8	12	3	4
Operating Leases	93	93						
Gross Debt	**3,746**	**93**	**481**	**280**	**358**	**772**	**466**	**1,296**

As of 3Q26. Excludes interest. Reflects figures post-refinancing. Y1 = October 2026 to September 2027, Y2 = October 2027 to September 2028, Y3 = October 2028 to September 2029, Y4 = October 2029 to September 2030, Y5 = October 2030 to September 2031, and Y6+ = October 2031 to September 2035.

Cashflow and Cash Conversion Cycle

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	YTD 26 (USD)	YTD 26	YTD 25	Δ YTD 26 vs YTD 25
Net cash from operating activities	**208**	**713**	**440**	**62%**
Net cash used in investing activities	**(25)**	**(86)**	**(119)**	**-27%**
Net cash used in financing activities	**(106)**	**(363)**	**(336)**	**8%**
Cash and cash equivalents at the end of the period	**179**	**614**	**226**	**172%**

	LTM Sep-25	LTM Jun-26	LTM Sep-26
Days Sales Outstanding	91	89	88
Days Inventory Outstanding	42	41	39
Days Payable Outstanding	142	141	142
Cash Conversion Cycle	**-9**	**-10**	**-15**

*Measured on an average basis according to last twelve months results.

Net cash from operating activities was S/713 million for the nine months ended September 30, 2026 versus S/440 million in the nine months ended September 30, 2025, and included a S/172 million increase in cash generated from operating activities, mainly related to a reduction in accounts receivable days and an improvement in collections in Peru and Mexico, as well as stable collections in Colombia, and to S/101 million in lower tax payments, primarily reflecting more efficient management of tax returns in Colombia, including the timely recovery of tax balances owed to Auna.

Net cash used in investing activities for the nine months ended September 30, 2026 was S/86 million, a decrease of 27% YoY, or S/33 million versus the comparable period last year. In YTD 2026 organic maintenance CapEx was S/111 million and included (i) S/71 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations, and (iii) a S/2 million payment to the Opción Oncología doctors for the brand acquisition. Additional investing cash flows included (iv) S/ 29 million cash inflow from Auna Seguros portfolio rebalancing, partially offset by (v) S/ 6 million earnout payment to IMAT Oncomedica shareholders.

In the nine months ended September 30, 2025, investing activities included: S/113 million in organic maintenance CapEx, including (i) S/66 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations; and (iii) an S/8 million payment to the Opción Oncología doctors for the brand acquisition. Other cash from investing activities included (iv) S/5 million in cash and cash equivalent inflows from Auna Seguros portfolio rebalancing of investments toward liquid securities, (v) a S/15 million payment to former OCA shareholders for holdback obligations, and (vi) a S/6 million earnout payment to IMAT Oncomedica shareholders.

Net cash used in financing activities was S/363 million, an increase of 8% or S/27 million, for the nine months ended September 30, 2026 versus the comparable period last year. Cash used in financing activities during the period included: (i) S/228 million in interest payments and hedge premium payments, (ii) S/34 million in interest payments for working capital facilities, and (iii) a S/101 million decrease in working capital borrowings. For the comparable nine months ended September 30, 2025, cash used in financing included: (i) S/247 million in interest and hedge premium payments, (ii) S/50 million in interest payments for working capital facilities, and (iii) a S/39 million decrease in working capital borrowings.

About AUNA

Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America's largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2026, Auna's network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,361 beds, and 1.4 million healthcare plans.

For more information visit www.aunainvestors.com

Conference Call Details

When: 8:00 a.m. Eastern time, November 18, 2026

Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.

Dial-in: +1 833-461-5787 (U.S. domestic), +1 585-542-9983 (International)
International Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers
Meeting ID: 489 711 788 (Passcode)
Webcast: click here

Definitions and Concepts

Figures in US dollars (US$ or USD) for 3Q26 are presented for indicative purposes and were calculated using an FX rate of US$1= S/3.4330. All comparisons in this announcement are year-over-year ("YoY"), unless otherwise noted; additionally, results are presented in an FX neutral basis ("FXN") for consolidated revenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted EBITDA, as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods.

Financial results are preliminary and subject to year-end audit.

Use of Non-IFRS Financial Measures

This release includes "non-IFRS financial measures", including: EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted LTM EBITDA, Segment EBITDA, Segment EBITDA Margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Consolidated Peru Adjusted EBITDA, Consolidated Peru Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Basic and Diluted EPS, Leverage Ratio, Free Cash Flow, and FX Neutral because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

In addition, management and our board of directors use these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our core operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth of our business. These are not measurements of operating performance under IFRS and have limitations as analytical tools. You should not consider such measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations of EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, FX Neutral and Leverage Ratio may be different from the calculations used by

other companies for similarly titled measures, including our competitors, and therefore may not be comparable to those of other companies.

EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board of directors to assess our financial performance.

EBITDA Margin: is calculated as EBITDA divided by total revenue from contracts with customers.

Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

Adjusted EBITDA Margin: is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.

Adjusted Last Twelve Month ("LTM") EBITDA: is calculated by adding the last four quarters beginning with the corresponding period.

Segment EBITDA: is calculated as segment profit before tax plus net finance cost and depreciation and amortization.

Segment EBITDA Margin: is calculated as segment EBITDA divided by total segment revenue from contracts with customers.

Segment Adjusted EBITDA: is calculated as segment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

Segment Adjusted EBITDA Margin: is calculated as segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	3Q'26 (USD)	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ 3Q'26 vs 2Q'26	Δ YTD 26 vs YTD 25
Revenues	**386**	**1,325**	**3,741**	**19%**	**7%**	**15%**
Profit (Loss) before Tax	**14**	**49**	**124**	**-50%**	**-18%**	**-57%**
(+) Net Finance Cost	33	112	359	56%	6%	80%
(+) Depreciation and Amortization	18	61	178	7%	5%	7%
(=) EBITDA	**65**	**222**	**660**	**-2%**	**0%**	**1%**
(+) Adjustments	2.7	9.2	15.3			
(a) Pre-operating expenses	0.1	*0.3*	*0.7*			
(b) Business development expenses	1.5	*5.2*	*6.0*			
(c) Stock-based consideration	1.1	*3.7*	*8.5*			
(d) Personnel non-recurring compensation	*0.0*	*0.0*	*0.0*			
(=) Adjusted EBITDA	**67**	**231**	**676**	**0%**	**2%**	**-3%**
Adjusted EBITDA Margin		*17.5%*	*18.1%*	*-3.3 p.p.*	*-0.9 p.p.*	*-3.3 p.p.*

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.
(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.
(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.
(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

For the three months ended September 30, 2026

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	**316**	**307**	**323**	**494**	**(115)**	**1,325**
Profit (Loss) before Tax	**11**	**21**	**53**	**15**	**(52)**	**49**
(+) Net Finance Cost	41	4	4	14	49	112
(+) Depreciation and Amortization	24	11	10	14	3	61
(=) Segment EBITDA	**76**	**36**	**67**	**43**	**0**	**222**
(+) Adjustments	7.3	0.4	0.4	0.2	0.8	9.2
Pre-operating expenses	*0.1*	*0.0*	*0.0*	*0.0*	*0.3*	*0.3*
Business development expenses	*5.2*	*0.0*	*0.0*	*0.0*	*0.0*	*5.2*
Stock-based consideration	*2.1*	*0.4*	*0.4*	*0.2*	*0.6*	*3.7*
Personnel non-recurring compensation	*0.0*	*0.0*	*0.0*	*0.0*	*0.0*	*0.0*
(=) Segment Adjusted EBITDA	**83**	**37**	**68**	**43**	**1**	**231**
Adjusted EBITDA Margin	26.3%	11.9%	20.9%	8.8%		17.5%

For the three months ended September 30, 2025

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	**264**	**279**	**294**	**369**	**(88)**	**1,117**
Profit (Loss) before Tax	**21**	**20**	**54**	**33**	**(31)**	**97**
(+) Net Finance Cost	33	9	3	6	21	72
(+) Depreciation and Amortization	22	12	9	11	3	57
(=) Segment EBITDA	**76**	**42**	**65**	**49**	**(7)**	**226**
(+) Adjustments	0.9	1.8	1.8	1.8	0.3	6.6
Pre-operating expenses	*0.0*	*0.0*	*0.0*	*0.0*	*-0.3*	*-0.3*
Business development expenses	*-1.0*	*1.6*	*1.6*	*1.7*	*0.0*	*3.8*
Stock-based consideration	*1.9*	*0.2*	*0.2*	*0.1*	*0.6*	*3.0*
Personnel non-recurring compensation	*0.0*	*0.0*	*0.0*	*0.0*	*0.0*	*0.0*
(=) Segment Adjusted EBITDA	**77**	**44**	**67**	**51**	**(6)**	**232**
Adjusted EBITDA Margin	29.0%	15.7%	22.9%	13.9%		20.8%

Year to date September 30, 2026

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	**895**	**885**	**954**	**1,321**	**(314)**	**3,741**
Profit (Loss) before Tax	**22**	**54**	**154**	**80**	**(186)**	**124**
(+) Net Finance Cost	131	15	17	27	169	359
(+) Depreciation and Amortization	70	32	31	36	8	178
(=) Segment EBITDA	**223**	**102**	**202**	**144**	**(10)**	**660**
(+) Adjustments	11.7	0.4	0.6	0.3	2.4	15.3
Pre-operating expenses	*0.1*	*0.0*	*0.0*	*0.0*	*0.6*	*0.7*
Business development expenses	*6.0*	*0.0*	*0.0*	*0.0*	*0.0*	*6.0*
Stock-based consideration	*5.5*	*0.4*	*0.6*	*0.3*	*1.7*	*8.5*
Personnel non-recurring compensation	0.0	0.0	0.0	0.0	0.0	0.0
(=) Segment Adjusted EBITDA	**234**	**102**	**202**	**145**	**-7**	**676**
Adjusted EBITDA Margin	26.2%	11.5%	21.2%	10.9%		18.1%

Year to date September 30, 2025

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	**781**	**812**	**861**	**1,054**	**(253)**	**3,253**
Profit (Loss) before Tax	**41**	**54**	**152**	**105**	**(62)**	**291**
(+) Net Finance Cost	106	27	13	13	39	199
(+) Depreciation and Amortization	65	36	27	31	8	166
(=) Segment EBITDA	**212**	**117**	**192**	**148**	**(15)**	**655**
(+) Adjustments	32.5	2.1	2.1	1.9	2.2	40.9
Pre-operating expenses	*0.0*	*0.0*	*0.0*	*0.0*	*0.4*	*0.4*
Business development expenses	*26.6*	*1.6*	*1.6*	*1.7*	*0.0*	*31.5*
Stock-based consideration	*5.3*	*0.5*	*0.5*	*0.2*	*1.8*	*8.3*
Personnel non-recurring compensation	0.6	0.0	0.0	0.0	0.0	0.6
(=) Segment Adjusted EBITDA	**245**	**119**	**194**	**150**	**-13**	**696**
Adjusted EBITDA Margin	31.4%	14.7%	22.6%	14.3%		21.4%

Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.

Consolidated Peru Adjusted EBITDA Margin: is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment, net of inter-segment eliminations.

Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	3Q'26 (USD)	3Q'26	3Q'25	YTD 26	YTD 25
Net Income (Loss)	**7**	**24**	**53**	**67**	**175**
(a) Pre-operating expenses	0.1	0.3	(0.3)	0.7	0.4
(b) Business development expenses	1.5	5.2	3.8	6.0	31.5
(c) Stock-based consideration	1.1	3.7	3.0	8.5	8.3
(d) Personnel non-recurring compensation	0.0	0.0	0.0	0.0	0.6
(e) Non-cash and non-recurring financial costs	1.6	5.6	1.1	16.4	1.1
(f) Allocated tax effects	(1.4)	(4.8)	(3.0)	(7.5)	(16.0)
(=) Adjusted Net Income	**10**	**35**	**58**	**91**	**201**

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.
(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.
(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.
(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.
(e) Non-cash and non-recurring financial costs include: 1) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT; and 2) withholding tax expenses associated with financing and refinancing activities.
(f) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.

Basic and Diluted Earnings per Share: Basic and Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	3Q'26 (USD)	3Q'26	3Q'25	YTD 26	YTD 25
Net Income (Loss)	**7**	**24**	**53**	**67**	**175**
Income (Loss) attributable to Owner of the company	*6*	*20*	*48*	*56*	*166*
Weighted average number of basic and diluted shares at September 30		*74.2*	*74.2*	*74.2*	*74.2*
Basic and diluted earnings per share	**0.08**	**0.27**	**0.65**	**0.76**	**2.23**
Adjusted Net Income (Loss)	**10**	**35**	**58**	**91**	**201**
Income (Loss) attributable to owners of Adjusted Net Income	*9*	*30*	*53*	*81*	*191*
Weighted average number of basic and diluted shares at September 30		*74.2*	*74.2*	*74.2*	*74.2*
Adjusted Basic and Diluted Earnings per Share	**0.12**	**0.41**	**0.71**	**1.09**	**2.58**

Leverage Ratio: We calculate Leverage Ratio as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Adjusted Last Twelve Months EBITDA.

(Figures in millions of Soles, unless expressed otherwise)

	Sep-25	Dec-25	Sep-26
Current and non-current loans & borrowings	3,526	3,533	3,600
Current and non-current lease liabilities	129	124	146
Cash and cash equivalents	226	335	614
Net Debt	3,429	3,321	3,133
Adjusted LTM EBITDA	951	917	896
Leverage Ratio	**3.6x**	**3.6x**	**3.5x**

Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents.

(Figures in millions of Soles, unless expressed otherwise)

	Sep-25	Dec-25	Sep-26
(+) Loans and borrowings	3,526	3,533	3,600
Short term debt	*658*	*316*	*465*
Long term debt	*2,868*	*3,216*	*3,136*
(+) Lease Liabilities	129	124	146
Gross Debt	**3,655**	**3,656**	**3,746**
(-) Cash and cash equivalents	226	335	614
Net Debt	**3,429**	**3,321**	**3,133**

Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities.

(Figures in millions of Soles, unless expressed otherwise)

	Sep-25	Sep-26
Cash generated from operating activities	**582**	**753**
(-) Income tax	155	*54*
(+) Interest received	13	*14*
Net cash from operating activities	**440**	**713**
Net cash used in investing activities	**(119)**	**(86)**
Free Cash Flow	**321**	**626**

FX Neutral: FX Neutral ("FXN") measures are prepared and presented to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, which may not be indicative of core operating results and business outlook.

FX Neutral measures are presented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analysts and the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or any other generally accepted accounting principles and should not be considered as a measure of performance in isolation.
The FX Neutral measures were calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these preceding periods until the date of the Company's most recent financial information.

The FX Neutral measures for the three months ended September 30, 2025 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the key business metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (MXN 5.2713 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (COP 1,131.3043 to PEN 1.00); then using such results to re-translate the corresponding amounts back to Peruvian soles by dividing them by the average Mexican pesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2026 (MXN 5.1038 to PEN 1.00 / COP 943.2503 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics would have been had exchange rates remained stable from this past period until the three months ended September 30, 2026.

Safe Harbor Statement

This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "project," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the execution of our strategic plan, including the recovery of our growth levels, our planned investments, our revenue, Adjusted EBITDA and capital expenditure guidance, our expectation for revenue and Adjusted EBITDA growth, the timeline for the construction and commencement of operations at the Centro Ambulatorio Trecca in Lima and our ability to recover any loss under the oncology risk-sharing contract in Colombia. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.

The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the "SEC").

Financial Guidance Disclaimer

Auna's guidance is based on management's current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.

Auna's financial guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company's Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the Leverage Ratio target and Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the "Safe Harbor Statement" section in this release.

IR Contact

Email: contact@aunainvestors.com

- Financial Tables Follow –

Balance Sheet (1/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	Sep-26 (USD)	Sep-26	Dec-25	Δ Sep-26 vs Dec-25
Assets				
Current assets				
Cash and cash equivalents	179	614	335	278
Trade accounts receivable	345	1,185	1,043	143
Other assets	61	211	259	(48)
Inventories	46	158	165	(7)
Insurance contract assets	-	-	13	(13)
Other investments	1	3	30	(27)
Total current assets	**632**	**2,171**	**1,845**	**326**
Non-current assets				
Trade accounts receivable	0	0	0	(0)
Other assets	9	30	27	3
Investments in associates and joint venture	10	35	30	5
Property furniture and equipment	701	2,405	2,287	118
Intangible assets	824	2,829	2,704	125
Right-of-use assets	38	131	113	18
Investment properties	2	7	6	0
Derivative financial instruments	16	56	54	2
Deferred tax assets	82	282	231	52
Other investments	0	1	1	(0)
Total non-current assets	**1,683**	**5,776**	**5,454**	**323**
Total assets	**2,315**	**7,947**	**7,298**	**649**

Balance Sheet (2/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	Sep-26 (USD)	Sep-26	Dec-25	Δ Sep-26 vs Dec-25
Liabilities				
Current liabilities				
Loans and borrowings	135	465	316	148
Lease liabilities	10	34	29	5
Trade accounts payable	348	1,196	1,053	143
Other accounts payable	85	291	225	65
Provisions	4	13	10	3
Derivative financial instruments	8	28	23	5
Insurance contract liabilities	5	18	9	9
Deferred income	0	1	0	0
Total current liabilities	**596**	**2,046**	**1,667**	**379**
Non-current liabilities				
Loans and borrowings	913	3,136	3,216	(80)
Lease liabilities	33	112	94	18
Trade accounts payable	0	0	1	(1)
Other accounts payable	69	236	222	14
Derivative financial instruments	6	21	40	(18)
Deferred tax liabilities	80	276	291	(15)
Deferred income	0	1	0	1
Total non-current liabilities	**1,102**	**3,783**	**3,865**	**(82)**
Total liabilities	**1,698**	**5,828**	**5,532**	**297**
Total equity	**617**	**2,119**	**1,766**	**352**
Total liabilities and equity	**2,315**	**7,947**	**7,298**	**649**

Income Statement

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	3Q'26 (USD)	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ YTD 26 vs YTD 25
Revenue					
Healthcare Services Mexico	92	316	895	20%	15%
Healthcare Services Colombia	144	493	1,318	35%	26%
- Healthcare Services Colombia	144	494	1,321	34%	25%
- Holding and eliminations	(0)	(1)	(4)	-74%	-4%
Healthcare Services Peru & Oncosalud Peru	150	516	1,528	6%	7%
- Healthcare Services Peru	89	307	885	10%	9%
- Oncosalud Peru	94	323	954	10%	11%
- Holding and eliminations	(33)	(114)	(310)	35%	24%
Total Revenue	**386**	**1,325**	**3,741**	**19%**	**15%**
Cost of sales and services	(256)	(879)	(2,421)	26%	20%
Gross profit	**130**	**446**	**1,319**	**6%**	**7%**
Gross margin		*33.7%*	*35.3%*	*-3.9 p.p.*	*-2.7 p.p.*
Selling expenses	(18)	(62)	(186)	5%	12%
Administrative expenses	(68)	(232)	(678)	16%	15%
(Loss) reversal for impairment of trade receivables	(1)	(3)	(11)	-48%	-62%
Other income and expenses, net	3	10	31	-13%	-4%
Operating profit	**46**	**158**	**475**	**-4%**	**-1%**
Finance income	2	7	15	63%	-1%
Finance income from exchange difference	0	0	0	-100%	-100%
Finance costs	(35)	(119)	(355)	3%	-1%
Finance costs from exchange difference	-	-	(19)	-	-
Net finance cost	**(33)**	**(112)**	**(359)**	**56%**	**80%**
Share of profit of equity accounted investees	1	3	8	-8%	-5%
Profit (loss) before tax	**14**	**49**	**124**	**-50%**	**-57%**
Income tax expense (benefit)	(7)	(24)	(58)	-45%	-50%
Net Income (Loss)	**7**	**24**	**67**	**-54%**	**-62%**
EBITDA					
Healthcare Services Mexico	22	76	223	0%	5%
Healthcare Services Colombia	13	43	144	-13%	-3%
Healthcare Services Peru & Oncosalud Peru	30	103	303	-4%	-2%
- Healthcare Services Peru	*11*	36	102	*-14%*	*-13%*
- Oncosalud Peru	*20*	67	202	*2%*	*5%*
Holding and eliminations	0	0	(10)		
Total EBITDA	**65**	**222**	**660**	**-2%**	**1%**
Adjusted EBITDA					
Healthcare Services Mexico	24	83	234	8%	-4%
Healthcare Services Colombia	13	43	145	-16%	-4%
Healthcare Services Peru & Oncosalud Peru	30	104	304	-6%	-3%
- Healthcare Services Peru	*11*	*37*	*102*	*-16%*	*-15%*
- Oncosalud Peru	*20*	*68*	*202*	*0%*	*4%*
Holding and eliminations	0	1	(7)		
Total Adjusted EBITDA	**67**	**231**	**676**	**0%**	**-3%**
Adjusted EBITDA Margin					
Healthcare Services Mexico		26.3%	26.2%	-2.7 p.p.	-5.2 p.p.
Healthcare Services Colombia		8.8%	10.9%	-5.1 p.p.	-3.3 p.p.
Healthcare Services Peru & Oncosalud Peru		20.2%	19.9%	-2.6 p.p.	-2.1 p.p.
- Healthcare Services Peru		*11.9%*	*11.5%*	-3.8 p.p.	-3.2 p.p.
- Oncosalud Peru		*20.9%*	*21.2%*	-2.0 p.p.	-1.4 p.p.
Adjusted EBITDA Margin		***17.5%***	***18.1%***	**-3.3 p.p.**	**-3.3 p.p.**

Statement of Cash Flows (1/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	YTD 26 (USD)	YTD 26	YTD 25	Δ YTD 26 vs YTD 25
Cash flows from operating activities				
(Loss) profit for the period	19	67	175	(108)
Adjustments for:				
Depreciation	27	91	86	5
Depreciation of right-of-use assets	6	22	21	1
Amortization	19	64	59	5
(Reversal) Impairment of inventories	0	1	0	0
Equity-settled share-based payment transactions	2	9	8	0
Gain (loss) on disposal of property furniture and equipment	0	0	(1)	2
Loss on disposal of right-of-use assets net of leases	-	-	(0)	0
(Reversal) loss for impairment of trade receivables	3	11	29	(18)
Share of profit of equity-accounted investees	(2)	(8)	(8)	0
Technical provisions and other provisions	1	5	1	4
Finance income	(4)	(15)	(161)	145
Finance costs	109	374	359	15
Tax expense	17	58	116	(58)
Net changes in assets and liabilities				
Trade accounts receivable and other assets	(21)	(72)	(132)	60
Inventories	5	19	(1)	20
Trade accounts payable and other accounts payable	32	109	35	73
Provisions and employee benefits	(1)	(2)	(4)	1
Insurance contract liabilities	6	22	(1)	23
Cash generated from operating activities	**219**	**753**	**582**	**171**
Income tax paid	(16)	(54)	(155)	101
Interest received	4	14	13	0
Net cash from operating activities	**208**	**713**	**440**	**273**

Statement of Cash Flows (2/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	YTD 26 (USD)	YTD 26	YTD 25	Δ YTD 26 vs YTD 25
Cash flows from investing activities				
Payment for accounts payables to former shareholder	(2)	(6)	(21)	14
Purchase of properties furniture and equipment	(21)	(71)	(66)	(4)
Purchase of intangibles	(12)	(41)	(47)	6
Dividends from equity-accounted investees	1	2	3	(1)
Purchase of other investments, net of sales	8	29	5	24
Proceeds from sale of property furniture and equipment	0	0	6	(6)
Net cash used in investing activities	**(25)**	**(86)**	**(119)**	**33**
Cash flows from financing activities				
Proceeds from settlement of derivatives - interest rate swaps	(6)	(19)	(9)	(10)
Proceeds from loans and borrowings	82	282	1,079	(797)
Payment for loans and borrowings	(102)	(349)	(1,084)	735
Payment for lease liabilities	(10)	(34)	(34)	(0)
Penalty paid for debt prepayment	(0)	(0)	(0)	(0)
Payment for derivatives premiums	(4)	(15)	(17)	2
Interest paid	(66)	(228)	(271)	43
Net cash used in financing activities	**(106)**	**(363)**	**(336)**	**(27)**
Net (decrease) increase in cash and cash equivalents	77	263	(15)	279
Cash and cash equivalents at January 1	98	335	236	100
Effect of movements in exchange rates on cash held	4	15	5	10
Cash and cash equivalents at the end of the period	**179**	**614**	**226**	**388**

Historical Financial Metrics

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	3Q'24	4Q'24	1Q'25	2Q'25	3Q'25	4Q'25	1Q'26	2Q'26	3Q'26
Revenue									
Oncosalud Peru	273	276	281	286	294	304	314	317	323
Healthcare Services Peru	255	245	263	269	279	273	281	296	307
Healthcare Services Colombia	363	353	339	346	369	387	400	427	494
Healthcare Services Mexico	316	268	243	274	264	258	279	300	316
Holding and eliminations	(80)	(79)	(84)	(81)	(88)	(89)	(96)	(103)	(115)
Total revenue from contracts with customers	**1,127**	**1,063**	**1,042**	**1,094**	**1,117**	**1,133**	**1,178**	**1,238**	**1,325**
Cost of sales and services	(677)	(629)	(660)	(660)	(698)	(704)	(747)	(796)	(879)
Gross profit	**449**	**434**	**382**	**434**	**419**	**429**	**431**	**442**	**446**
Selling expenses	(55)	(42)	(54)	(54)	(59)	(54)	(62)	(62)	(62)
Administrative expenses	(195)	(201)	(182)	(208)	(200)	(222)	(214)	(232)	(232)
Impairment losses on trade receivables	(25)	(13)	(16)	(8)	(5)	(19)	(9)	0	(3)
Other expenses	0	(2)	0	0	0	0	0	0	0
Other income	54	14	9	12	11	11	9	13	10
Operating profit	**229**	**190**	**139**	**176**	**166**	**144**	**155**	**162**	**158**
Finance income	6	7	6	5	4	6	4	5	7
Finance income from exchange difference	28	(31)	37	68	40	48	0	0	0
Finance costs	(138)	(138)	(123)	(120)	(116)	(292)	(118)	(118)	(119)
Finance costs from exchange difference	0	8	0	0	0	0	(26)	8	0
Net finance cost	**(103)**	**(155)**	**(80)**	**(46)**	**(72)**	**(238)**	**(141)**	**(105)**	**(112)**
Share of profit of equity-accounted investees	2	2	3	2	3	2	3	2	3
Profit (loss) before tax	**127**	**37**	**62**	**132**	**97**	**(91)**	**16**	**59**	**49**
Income tax (expense) benefit	(27)	(13)	(24)	(48)	(44)	27	(7)	(26)	(24)
Net Income	**101**	**24**	**38**	**84**	**53**	**(64)**	**9**	**33**	**24**
EBITDA	**286**	**244**	**195**	**234**	**226**	**203**	**215**	**223**	**222**
EBITDA Adjustments									
Net Income	101	24	38	84	53	(64)	9	33	24
Income tax expense	27	13	24	48	44	(27)	7	26	24
Net finance cost	103	155	80	46	72	238	141	105	112
Depreciation and amortization	*55*	*52*	*53*	*55*	*57*	*56*	*57*	*59*	*61*
(a) Pre-operating expenses	*0*	*0*	*0*	*0*	*(0)*	*0*	*0*	*0*	*0*
(b) Business development expenses	*(44)*	*3*	*24*	*4*	*4*	*10*	*0*	*1*	*5*
(c) Change in fair value of earn-out liabilities	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*
(d) Stock-based consideration	*6*	*3*	*3*	*3*	*3*	*3*	*2*	*3*	*4*
(e) Personnel non-recurring compensation	*2*	*5*	*0*	*0*	*0*	*5*	*0*	*0*	*0*
(f) Change in fair value of investment properties	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*
Adjusted EBITDA	**250**	**254**	**222**	**241**	**232**	**220**	**217**	**227**	**231**

Key Operating Metrics

	3Q'26	YTD 26	Δ 3Q'26 vs 3Q'25	Δ YTD 26 vs YTD 25
Oncosalud Peru				
Plan memberships [1] [2]	1,441,794	1,441,794	3%	3%
Average monthly revenue per plan member [3]	S/ 65.15	S/ 64.02	5%	5%
Preventive check-ups [4]	25,084	81,883	-14%	-13%
Patients treated [5]	56,127	153,625	34%	28%
Medical loss ratio [6]		58.7%		4.2 p.p
Healthcare Services				
Total bed capacity [1][7]	2,252	2,252	1%	1%
Protected Lives [8]	3,208,686	3,208,686	6%	6%
Surgeries [9]	23,932	67,454	12%	7%
Emergency treatments [10]	101,257	290,540	8%	9%
Chemotherapies & Radiotherapies [11]	55,439	162,888	7%	6%
Total number of days hospitalized [12]	144,041	418,206	6%	5%
Operating capacity utilization [13]	78.4%	76.7%	3.2 p.p	2.3 p.p
Total capacity utilization [14]	69.5%	68.0%	3.1 p.p	2.3 p.p

1) As of period end.
2) As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of September 30, 2026, we had 1,341,825 active members and 99,969 inactive members.
3) Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period.
4) Preventive check-ups consider Oncosalud and Healthcare plan check-ups, including for Auna Corporate plans, receiving check-ups at the Centro de Bienestar Ambulatorio – CBA (Wellness Center) in Lima and at other facilities in Peru.
5) Number of individual plan members in Oncosalud and Healthcare plans, including Auna Corporate plans, receiving treatment during the period in Peru. Each plan member is counted once for a trimester, however, might have received multiple instances of treatment throughout the year.
6) MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans.
7) Includes all beds within the Healthcare Network and excludes 109 Oncology beds.
8) Insured population assigned to Auna under risk-sharing agreements in Colombia.
9) Number of surgeries includes surgeries, outpatient surgeries and cesarean sections.
10) Emergency care includes the number of visits in the emergency room and may include several visits per patient.

11) Intravenous chemotherapy and radiotherapy infusions in both inpatient and outpatient care; excludes oral treatments. In Peru, includes sessions across the Healthcare Services Network and Oncosalud Segments.
12) Total number of days during which any of Auna's beds were occupied by a hospitalized patient during the period, including ICU.
13) Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period.
14) Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.